Insider Selling: Singular Genomics Systems, Inc. (NASDAQ:OMIC) CEO Sells 800 Shares of Stock

Singular Genomics Systems, Inc. (NASDAQ:OMIC) CEO Andrew Spaventa sold 800 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $19.89, for a total transaction of $15,912.00. Following the completion of the transaction, the chief executive officer now directly owns 1,432 shares of the company’s stock, valued at approximately $28,482.48. This trade represents a 35.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Andrew Spaventa also recently made the following trade(s):

• On Monday, December 16th, Andrew Spaventa sold 180 shares of Singular Genomics Systems stock. The shares were sold at an average price of $20.16, for a total transaction of $3,628.80.

Singular Genomics Systems Stock Up 0.1 %

OMIC stock opened at $19.96 on Monday. The company’s 50 day simple moving average is $19.79 and its 200-day simple moving average is $16.04. The firm has a market capitalization of $50.70 million, a PE ratio of -0.57 and a beta of 1.83. Singular Genomics Systems, Inc. has a 12 month low of $5.34 and a 12 month high of $23.41. The company has a debt-to-equity ratio of 0.04, a current ratio of 7.37 and a quick ratio of 6.67.

Institutional Trading of Singular Genomics Systems

A hedge fund recently raised its stake in Singular Genomics Systems stock. Geode Capital Management LLC grew its holdings in Singular Genomics Systems, Inc. (NASDAQ:OMIC) by 7.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,962 shares of the company’s stock after purchasing an additional 1,193 shares during the quarter. Geode Capital Management LLC owned approximately 0.72% of Singular Genomics Systems worth $282,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 65.80% of the company’s stock.

About Singular Genomics Systems

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.